Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(89)90507-3 ◽

1989 ◽

Vol 161 (2) ◽

pp. 309-312 ◽

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Neil Rosenshein ◽

Guy Photopulos ◽

Philip J. DiSaia

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.055 ◽

2015 ◽

Vol 137 ◽

pp. 24 ◽

Author(s):

K.N. Moore ◽

M. Sill ◽

M.E. Tenney ◽

C.J. Darus ◽

D. Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Download Full-text

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/0090-8258(92)90055-n ◽

1992 ◽

Vol 44 (3) ◽

pp. 268-270 ◽

Author(s):

Allan J. Jacobs ◽

John A. Blessing ◽

Alan Munoz

Keyword(s):

Cervical Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79511-7 ◽

2010 ◽

Vol 2010 ◽

pp. 73-74

Author(s):

J.T. Thigpen

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Her2 Positive ◽

Oncology Group Study

Download Full-text

Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.05.016 ◽

2005 ◽

Vol 98 (2) ◽

pp. 294-298 ◽

Author(s):

Howard D. Homesley ◽

John A. Blessing ◽

Joel Sorosky ◽

Gary Reid ◽

Katherine Y. Look

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study

American Journal of Clinical Oncology ◽

10.1097/00000421-198406000-00012 ◽

1984 ◽

Vol 7 (3) ◽

pp. 261-264 ◽

Author(s):

J. Tate Thigpen ◽

John A. Blessing ◽

James C. Arseneau ◽

Howard D. Homesley

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Carcinoma Of The Ovary

Download Full-text

Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6491 ◽

2002 ◽

Vol 84 (2) ◽

pp. 241-244 ◽

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Nader Husseinzadeh ◽

Kenneth D. Webster ◽

Janet S. Rader ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.08.027 ◽

2018 ◽

Vol 151 (2) ◽

pp. 257-263 ◽

Author(s):

William P. Tew ◽

Michael W. Sill ◽

Joan L. Walker ◽

Angeles Alvarez Secord ◽

Albert J. Bonebrake ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.06.022 ◽

2011 ◽

Vol 123 (1) ◽

pp. 19-26 ◽

Author(s):

Kian Behbakht ◽

Michael W. Sill ◽

Kathleen M. Darcy ◽

Stephen C. Rubin ◽

Robert S. Mannel ◽

...

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Tumor Biomarkers ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text